# A Review of Vagus Nerve Stimulation for Disease: Comprehensive Theory and Evidence for Mechanisms of Action

**Authors:** Yifeng Bu, Alex Liang, Benjamin U. Hoffman, Dawn M. Schiehser, Oliver Case, Alan Simmons, Ruth Klaming, Andres Gottfried‐Blackmore, Ravinder K. Mittal, Christopher Puleo, Hubert Lim, Imanuel Lerman

PMC · DOI: 10.1002/cph4.70109 · Comprehensive Physiology · 2026-03-04

## TL;DR

This paper reviews how vagus nerve stimulation affects various body systems and offers insights into its mechanisms and future improvements.

## Contribution

The paper provides a unified synthesis of VNS mechanisms across multiple organ systems, addressing a critical gap in the field.

## Key findings

- VNS modulates functions through neuromodulator release, synaptic plasticity, and autonomic regulation.
- The review identifies limitations like biological heterogeneity and proposes innovations such as AI-guided personalization.
- It serves as a foundational resource for advancing bioelectronic medicine and precision neuromodulation.

## Abstract

Vagus nerve stimulation (VNS) is an established neuromodulatory therapy approved for epilepsy, depression, obesity, stroke rehabilitation, rheumatoid arthritis, migraine, and cluster headaches. Its therapeutic potential has expanded dramatically, with growing evidence supporting its efficacy across a wide spectrum of neurological, psychiatric, cardiovascular, immunological, metabolic, and gastrointestinal disorders. Despite this progress, the field has lacked a comprehensive synthesis that unifies mechanistic insights with translational applications across organ systems. This review addresses that gap by systematically integrating current knowledge in the multifactorial mechanisms through which VNS modulates central and peripheral functions, including neuromodulator release, synaptic plasticity, autonomic regulation, neuroimmune control, and endocrine integration. In addition, this review identifies key limitations of VNS, including biological heterogeneity, technical constraints, and methodological variability, and proposes future innovations such as selective fiber targeting, closed‐loop systems, and artificial intelligence‐guided personalization. By providing a rigorous, system‐level overview of VNS mechanisms and their translational relevance, this article serves as a foundational resource for advancing the science and clinical deployment and helping illustrate future directions for precision neuromodulation and bioelectronic medicine.

Vagus nerve stimulation (VNS) effects span central and peripheral organ systems through diverse mechanistic pathways. This comprehensive review provides a unified synthesis of these mechanisms across neurological, cardiovascular, immunological, metabolic, and gastrointestinal domains, filling a critical gap and serving as a foundational resource for bioelectronic medicine.

## Linked entities

- **Diseases:** epilepsy (MONDO:0005027), depression (MONDO:0002050), obesity (MONDO:0011122), stroke (MONDO:0005098), rheumatoid arthritis (MONDO:0008383), migraine (MONDO:0005277), cluster headaches (MONDO:0043537)

## Full-text entities

- **Genes:** IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, Dnm1l (dynamin 1-like) [NCBI Gene 114114] {aka DLP1, Dnml1, Drp1}, CHAT (choline O-acetyltransferase) [NCBI Gene 1103] {aka CHOACTASE, CMS1A, CMS1A2, CMS6}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, TAC1 (tachykinin precursor 1) [NCBI Gene 6863] {aka Hs.2563, NK2, NKNA, NPK, TAC2}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, ACHE (acetylcholinesterase (Yt blood group)) [NCBI Gene 43] {aka ACEE, ARACHE, N-ACHE, YT}, POMC (proopiomelanocortin) [NCBI Gene 5443] {aka ACTH, CLIP, LPH, MSH, NPP, OBAIRH}, CLDN5 (claudin 5) [NCBI Gene 7122] {aka AWAL, BEC1, CPETRL1, TMDVCF, TMVCF}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, FUS (FUS RNA binding protein) [NCBI Gene 2521] {aka ALS6, ETM4, FUS1, HNRNPP2, POMP75, TLS}, ADRB2 (adrenoceptor beta 2) [NCBI Gene 154] {aka ADRB2R, ADRBR, ARB2, B2AR, BAR, BETA2AR}, TJP1 (tight junction protein 1) [NCBI Gene 7082] {aka ZO-1}, CMA1 (chymase 1) [NCBI Gene 1215] {aka CYH, MCT1, chymase}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, CHRNA7 (cholinergic receptor nicotinic alpha 7 subunit) [NCBI Gene 1139] {aka CHRNA7-2, NACHRA7, a7nAChR, nAChR7}, SREBF1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 6720] {aka HMD, IFAP2, SREBP1, bHLHd1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, CCK (cholecystokinin) [NCBI Gene 609547], Npy2r (neuropeptide Y receptor Y2) [NCBI Gene 18167] {aka NPY2-R}, Cpt1a (carnitine palmitoyltransferase 1A) [NCBI Gene 25757] {aka CPT-Ia}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}, Prkaa2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 78975] {aka Ampk, Ampka2}, CRH (corticotropin releasing hormone) [NCBI Gene 1392] {aka CRF, CRH1}, VIP (vasoactive intestinal peptide) [NCBI Gene 7432] {aka PHM27}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, GCK (glucokinase) [NCBI Gene 2645] {aka FGQTL3, GK, GLK, HHF3, HK4, HKIV}, P2ry1 (purinergic receptor P2Y, G-protein coupled 1) [NCBI Gene 18441] {aka P2Y1, P2y1r}, FOXO1 (forkhead box O1) [NCBI Gene 2308] {aka FKH1, FKHR, FOXO1A}, AGT (angiotensinogen) [NCBI Gene 183] {aka ANHU, SERPINA8, hFLT1}, Chrna7 (cholinergic receptor, nicotinic, alpha polypeptide 7) [NCBI Gene 11441] {aka Acra7, alpha7, nAChR7, nAchR}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, CAT (catalase) [NCBI Gene 847], Mfn2 (mitofusin 2) [NCBI Gene 64476] {aka HSG}, AQP4 (aquaporin 4) [NCBI Gene 361] {aka MIWC, MLC4, WCH4, hAQP4}, CASP1 (caspase 1) [NCBI Gene 834] {aka ICE, IL1BC, P45}, Opa1 (OPA1, mitochondrial dynamin like GTPase) [NCBI Gene 171116], IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, ANG (angiogenin) [NCBI Gene 283] {aka ALS9, HEL168, RAA1, RNASE4, RNASE5}, GAL (galanin and GMAP prepropeptide) [NCBI Gene 51083] {aka ETL8, GAL-GMAP, GALN, GLNN, GMAP}, GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, TH (tyrosine hydroxylase) [NCBI Gene 7054] {aka DYT14, DYT5b, TYH}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, CCK (cholecystokinin) [NCBI Gene 885], Fis1 (fission, mitochondrial 1) [NCBI Gene 288584] {aka Ttc11}, INS (insulin) [NCBI Gene 397415], GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, NMU (neuromedin U) [NCBI Gene 10874], STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}
- **Diseases:** metabolic disorders (MESH:D008659), Seizure (MESH:D012640), multiple sclerosis (MESH:D009103), septic shock (MESH:D012772), psoriatic arthritis (MESH:D015535), post-traumatic headache (MESH:D051298), dyspepsia (MESH:D004415), hearing loss (MESH:D034381), ischemia (MESH:D007511), bloating (MESH:C535647), vocal cord paralysis (MESH:D014826), major depression (MESH:D003865), Neurological Disorders (MESH:D009461), immune dysregulation (OMIM:614878), hypoxic ischemic encephalopathy (MESH:D020925), myocardial necrosis (MESH:D009336), liver lipid (MESH:D011017), panic disorder (MESH:D016584), tuberous sclerosis (MESH:D014402), hyperactive (MESH:D006948), O'Reilly (MESH:C535508), PTSD (MESH:D013313), OUD (MESH:D009293), Migraine (MESH:D008881), bronchospasm (MESH:D001986), Acute MI (MESH:D000208), ARDS (MESH:D012128), arrhythmic (OMIM:212500), septic (MESH:D001170), SLE (MESH:D008180), ulcerative colitis (MESH:D003093), brain tissue damage (MESH:D017695), CAP (MESH:C535672), systole (MESH:D000092244), axonal injury (MESH:D001480), Coma (MESH:D003128), cognitive and motor impairments (MESH:D003072), Anxiety Disorders (MESH:D001008), hypoxemia (MESH:D000860), vomiting (MESH:D014839), analgesia (MESH:D000699), and memory impairments (MESH:D008569), bradycardia (MESH:D001919), SSc (MESH:D012595), Sepsis (MESH:D018805), Post-COVID-19 Condition (MESH:D000094024), CRS-R (MESH:D003398), Bulimia Nervosa (MESH:D052018), phantom sound (MESH:D010591), chronic (MESH:D002908), underweight (MESH:D013851), epileptiform (MESH:D014277), Mood Disorders (MESH:D019964), gastric hypersensitivity (MESH:D013272), in verbal fluency (MESH:D013064), social anxiety disorder (MESH:D000072861), unresponsive wakefulness syndrome (MESH:C567934), cytokine storm (MESH:D000080424), LC degeneration (MESH:D009410), IBS (MESH:D043183)
- **Chemicals:** NAD+ (MESH:D009243), DA (MESH:D004298), NE (MESH:D009638), GABA (MESH:D005680), iron-oxide (MESH:C000499), glutamate (MESH:D018698), alcohol (MESH:D000438), kynurenine (MESH:D007737), NO (MESH:D009569), Glucose (MESH:D005947), 5-HT (MESH:D012701), CAMP (MESH:D000242), calcium (MESH:D002118), ROS (MESH:D017382), excitatory amino acids (MESH:D018846), blood glucose (MESH:D001786), ATP (MESH:D000255), E (MESH:D004540), s-nitrosoglutathione (MESH:D026422), steroid (MESH:D013256), luminal (MESH:D010634), GSH (MESH:D005978), Lipid (MESH:D008055), glycogen (MESH:D006003), LPS (MESH:D008070), guanfacine (MESH:D016316), atropine (MESH:D001285), ACh (MESH:D000109), catecholamine (MESH:D002395), aspartate (MESH:D001224), lactate (MESH:D019344), cortisol (MESH:D006854), cocaine (MESH:D003042), aldosterone (MESH:D000450), triglyceride (MESH:D014280), adrenaline (MESH:D004837), fatty acid (MESH:D005227), MDA (MESH:D008315), bicarbonate (MESH:D001639), ABVN (-), thyroxine (MESH:D013974), histamine (MESH:D006632), sodium (MESH:D012964), oxygen (MESH:D010100)
- **Species:** Sus scrofa (pig, species) [taxon 9823], Ovis aries (domestic sheep, species) [taxon 9940], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Rodentia (rodent, order) [taxon 9989], Canis lupus familiaris (dog, subspecies) [taxon 9615], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12960021/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12960021/full.md

## References

667 references — full list in the complete paper: https://tomesphere.com/paper/PMC12960021/full.md

---
Source: https://tomesphere.com/paper/PMC12960021